Filing Flows › Edwards Lifesciences (EW) › Guidance history
Edwards Lifesciences (EW) guidance history: what it guided and what it reported
Edwards Lifesciences gave guidance in 12 earnings releases on file since Feb 6, 2024. Of 9 guided periods since reported, it met or beat its own guidance 8 times (89%). Revenue: 8 of 9, on average +0.4% against the guided midpoint. Its releases raised guidance 10 times and lowered it twice.
Revenue
Met or beat 8 of 9 periods (4 above, 4 within, 1 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| Q4 2026 | $1.7B–$1.8B (Nov 4, 2026) | — | to be reported | — |
| Q3 2026 | $1.6B–$1.7B (Jul 23, 2026) | $1.7B | above the range | +2.7% |
| Q2 2026 | $1.7B–$1.7B (Apr 23, 2026) | $1.7B | within the range | +2.4% |
| FY2026 | $6.5B–$6.9B (Apr 23, 2026) → raised $6.6B–$6.9B (Jul 23, 2026) | — | to be reported | — |
| Q1 2026 | $1.6B–$1.6B (Feb 10, 2026) | $1.6B | above the range | +3.7% |
| Q4 2025 | $1.5B–$1.6B (Oct 30, 2025) | $1.6B | within the range | +1.3% |
| FY2025 | $5.7B–$6.1B (Apr 23, 2025) → raised $5.9B–$6.1B (Jul 24, 2025) | $6.1B | within the range | +1.1% |
| Q3 2025 | $1.5B–$1.5B (Jul 24, 2025) | $1.6B | above the range | +3.5% |
| Q2 2025 | $1.4B–$1.5B (Apr 23, 2025) | $1.5B | above the range | +2.8% |
| Q1 2025 | $1.4B–$1.4B (Feb 11, 2025) | $1.4B | within the range | +1.6% |
Gross margin
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | 78.0%–79.0% (Jul 23, 2026) | — | to be reported | — |
| FY2025 | 77.5% (Jul 24, 2025) | — | — | — |
| Q4 2024 | 76.0%–78.0% (Oct 24, 2024) | — | — | — |
Adjusted gross margin
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | 78.0%–79.0% (Feb 10, 2026) → reaffirmed 78.0%–79.0% (Nov 4, 2026) | — | to be reported | — |
| FY2025 | 78.0%–79.0% (Feb 11, 2025) → lowered 77.9% (Oct 30, 2025) | — | — | — |
Operating margin
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| Q4 2026 | 9.6% (Feb 10, 2026) | — | to be reported | — |
| FY2025 | 27.0%–28.0% (Apr 23, 2025) | — | — | — |
Adjusted operating margin
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2025 | 27.0%–28.0% (Feb 11, 2025) | — | — | — |
Adjusted tax rate
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | 16.0%–19.0% (Jul 23, 2026) → reaffirmed 16.0%–19.0% (Nov 4, 2026) | — | to be reported | — |
| FY2024 | 8.4% (Jul 24, 2024) | — | — | — |
The latest quarter
Edwards Lifesciences, Q3 2026: revenue $1.7B (+10% year over year), operating margin 17.4%, net earnings $308M, operating cash flow $570M. The chart follows the revenue to costs, profit and cash.
Questions
Does Edwards Lifesciences beat its guidance?
Edwards Lifesciences gave guidance in 12 earnings releases on file since Feb 6, 2024. Of 9 guided periods since reported, it met or beat its own guidance 8 times (89%). Revenue: 8 of 9, on average +0.4% against the guided midpoint.
How often does Edwards Lifesciences raise guidance?
Its earnings releases raised guidance 10 times and lowered it twice since Feb 6, 2024.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.